Curiox Biosystems makes 'Laminar Wash' instruments that wash and stain cells without a centrifuge, cutting sample-preparation time from about 30 minutes to roughly 2 minutes. It automates an essential step in drug discovery and precision-medicine research, has secured a good number of the world's top pharmaceutical companies as customers, and has recently been growing the share of recurring revenue through installed software (Fluto Code). Over this window there were the March business report and shareholders' meeting, the May first-quarter report, and an April holdings report, but no single disclosure prominent enough to move the share price sharply. What stands out recently is that its technical position in cell-preparation automation, its large-pharma customer base, its cash-rich finances, and its accelerating revenue growth are strengths, but it is still lossmaking and, as a P/S of 141x indicates, growth expectations are already heavily priced in, so the key question is whether high-margin software revenue can actually narrow the losses and demonstrate a path to profitability.
At-a-glance assessment financial health · growth · profitability · valuation
- The most recent full-year net result was a loss.
- Revenue rose 12.3% year over year, and the pace is quickening (3-year trend: mixed).
- Most recent quarter (Q1 2026) revenue was 43.7% higher than a year earlier.
- ROE is -51.5% (controlling-interest basis). It is below the sector average.
- Operating margin is -239.0%.
- P/E is hard to compute here, so this is read on P/B.
Ownership & governance As of 2025-12-31
Largest shareholder Kim Nam-yong 17.03% (individual)
Controlling bloc incl. related parties 17.4%
With the controlling bloc holding 17%, control is maintained but the free float is relatively large.
🔎 In-depth analysis
- Curiox Biosystems makes and sells instruments that automate the preparation step before cells are analyzed.
- Its flagship product, 'Laminar Wash,' lets cells be washed and stained without running them through a centrifuge, cutting sample preparation that used to take 30 minutes to roughly 2 minutes.
- Because this cell preparation is an essential step in drug discovery and precision-medicine research such as flow cytometry and single-cell analysis, the company says it has secured a good number of the world's top pharmaceutical companies as customers.
- Recently, it has been shifting its center of gravity beyond instrument sales toward a high-margin structure that earns recurring revenue through installed software (Fluto Code), and it aims to generate more than half of its revenue from software.
- The latest close is ₩39,700 and the market cap is ₩683 billion.
- The price sits below the 20-day line (₩49,025) and the 60-day line (₩75,998).
- Trading below both the short- and medium-term moving averages, the trend looks subdued.
- The RSI (a gauge that compares upward and downward strength over the past 14 days on a 0-100 scale) is 31.3, a neutral level.
- The one-month change is -42.6% and the three-month change is -49.6%, and the price is -71.6% from its 52-week high.
- Relative strength versus the KOSDAQ is 51 (on a 1-99 scale, converting the past year's return versus the index with more weight on recent periods; higher means stronger than the market), placing it in roughly the top 49% of all stocks by strength.
- Over the past three months it lagged the index by 35.6%.
- Chart readings are best viewed together with trading volume and the dates of disclosures.
- This company is not yet turning a profit.
- In 2025 revenue was only ₩5.15 billion, against an operating loss of ₩12.3 billion and a net loss of ₩27.2 billion.
- So the P/E ratio (how many times one year's profit the price represents) is not calculable given the loss, while the P/B (how many times book equity the price represents) is 12.93x and the P/S (how many times annual revenue the price represents) is a very high 141x.
- This high multiple means that not today's small revenue but future growth expectations are embedded in the ₩729.4 billion market cap.
- The finances themselves are not precarious.
- Net debt is negative, meaning it holds ₩12.3 billion more cash than debt, a net-cash position, and the current ratio (assets readily usable relative to debt due within a year) is a stable 1.7x.
- However, it does not yet earn cash from operations, so free cash flow (FCF, the cash that actually remains in hand) is negative, and it is in a phase of investing in growth by spending its cash.
- ROE (how much is earned in a year on equity) of -51% likewise shows it is at a stage before turning profitable.
- The direction of growth is intact.
- Revenue rose 12.3% year over year in 2025, and most recently first-quarter 2026 revenue jumped 43.7% year over year to ₩1.32 billion.
- Notably, the pace of revenue growth is actually accelerating.
- Growth has two drivers.
- One is the spread of the instruments themselves; the other is the newly launched software (Fluto Code) revenue.
- Software brings in money repeatedly once sold and carries high margins, so the larger its share, the more the losses narrow.
- That said, the revenue base is still small and does not yet cover fixed costs, so losses continue.
- No official target figure for this year's net profit has been confirmed, so it is honest to leave the timing of a swing to profitability as an open variable.
- Recent disclosures have been more about governance and holdings than about earnings or orders.
- In March 2026 the business report and annual shareholders' meeting came out, followed by the May first-quarter report, and in April there were reports of changes in the holdings of executives and major shareholders and a large-holding report.
- At the end of March there was also a notice of a stock-option grant, in the nature of retaining talent through employee compensation.
- No standalone disclosure of a large supply contract or preliminary results, capable of moving the share price sharply, stood out in this window.
- It is therefore more accurate to read the current share price as reflecting the market's re-valuation of growth expectations and continued losses rather than any individual disclosure.
- This is an early-stage growth company with distinct strengths and weaknesses.
- The strengths are a clear technical position in cell-preparation automation, a base of large global pharmaceutical customers, and a stable balance sheet with more cash than debt.
- The pace of revenue growth is even accelerating.
- The weaknesses are clear.
- It is still lossmaking, and as a P/S of 141x indicates, growth expectations were already heavily priced into the share price.
- As those expectations wavered, the share price fell nearly 70%.
- Ultimately the focus narrows to one thing: whether high-margin software revenue can actually scale up to narrow the losses and show a path to profitability.
- If that swing is confirmed, it becomes a strong stock; if revenue growth fails to carry through into software, it is a stock whose high valuation is hard to justify.
🔎 Valuation vs peers Inconclusive
Because cell-analysis and preparation automation is an early-commercialization bio-instrument area with no obvious listed domestic peers, judgment is based on the growth stage and the character of the revenue-based valuation rather than on comparing specific-stock multiples.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Curiox Biosystems | 0.00x | 12.93x | -51.47% |
Because the company is lossmaking, a P/E cannot distinguish under- from overvaluation, and the remaining metrics, a P/B of 13.8x and a P/S of 141x, reflect future growth expectations rather than current results. The positive direction, with revenue rising quickly and the software transition underway, is clear, but the timing and scale of a swing to profitability are not yet confirmed in figures. For a growth stock at a stage before earnings emerge, it is hard to declare a valuation right or wrong until future results are confirmed. It is therefore more honest to remain inconclusive than to pin it as under- or overvalued, and whether software revenue actually scales up to narrow the losses is the key variable that will decide the direction of the valuation ahead.
Price history Close · MA20 · MA60
The latest close is ₩39,700 and the market capitalization is ₩683.0 billion. The price sits below its 20-day moving average (₩49,025) and below its 60-day moving average (₩75,998). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 31.3, a neutral level. The one-month change is -42.6%, the three-month change is -49.6%, and the position relative to the 52-week high is -71.6%. Relative strength versus the KOSDAQ is 51 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 51% of all stocks. Over the past three months it lagged the index by 35.6%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -35.59% / 6M -58.44% / 12M -10.86%
Key metrics vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 12.93x is above the sector median (1.61x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is -51.5%, below the sector average (5.0%). The operating margin is -239.0%. The debt ratio is 147.8%, so the financial structure is moderate.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $4.5M | $3.0M | $3.4M | +12.29% ↑ faster |
| Operating profit | -$7.0M | -$8.9M | -$8.2M | — |
| Net profit | -$6.7M | -$5.4M | -$18.0M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $4.5M | $3.0M | $3.4M |
| Operating profit | — | — | -$7.0M | -$8.9M | -$8.2M |
| Net profit | — | — | -$6.7M | -$5.4M | -$18.0M |
| Revenue CAGR | 2-yr avg -12.88% | ||||
Revenue rose 12.3% year over year (2023 ₩6.8 billion → 2024 ₩4.6 billion → 2025 ₩5.2 billion), and the three-year trend is 'mixed'. The pace of growth also quickened from the prior year. Operating results are in the red, so a swing back to profit matters more than the growth rate here. Over the 3 years on record, revenue compound annual growth (CAGR) is -12.9%. The two-year revenue CAGR is -12.9%. In the most recent quarter (Q1 2026), revenue was 43.7% higher than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- Revenue grew 12.3% year over year, a sign of growth.
Points to watch
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-05-15FilingQ1 2026 quarterly report filed. Revenue ₩1.32 billion, up 43.7% year over year, with a continuing operating loss of ₩3.25 billion and net loss of ₩2.64 billion.The faster pace of revenue growth is positive, but with losses continuing, the timing of a swing to profitability remains something to watch. Source
- 2026-04-17FilingLarge-holding report filed. Changes in major shareholders' holdings were disclosed.Shifts in major-shareholder flows are a reference for free float and governance stability. Source
- 2026-03-31FilingAnnual shareholders' meeting results disclosed. Regular agenda items such as approval of the financial statements were handled.As a routine governance and board procedure, the short-term impact on the share price is limited. Source
- 2026-03-31FilingNotice of a stock-option grant filed. For employee compensation and talent retention.Helps retain key talent, but should also be viewed as a factor that may increase the share count (dilution) later. Source
- 2026-03-23FilingFY2025 business report filed. Annual revenue ₩5.15 billion (+12.3%), operating loss ₩12.3 billion, net loss ₩27.2 billion confirmed.Revenue is growing, but the wide loss confirms that restoring profitability is the key task. Source
Figure cross-check computed ↔ external
Recent filings
- 2026-05-15PeriodicQuarterly report
- 2026-04-17OwnershipOwnership-change filing
- 2026-04-10OwnershipOfficers'/major-shareholders' holdings report
- 2026-04-10OwnershipOfficers'/major-shareholders' holdings report
- 2026-04-10OwnershipOfficers'/major-shareholders' holdings report
- 2026-04-10OwnershipOfficers'/major-shareholders' holdings report
- 2026-04-01Disclosure
- 2026-03-31Shareholders' meeting notice
- 2026-03-31Disclosure
- 2026-03-23PeriodicAnnual business report
- 2026-03-19Audit report
- 2026-03-04Disclosure
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.